Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / Monoclonal and Polyclonal Antibodies Research · Journal article
Stem Cell Research & Therapy · September 6, 2026
A consensus or society position rather than new primary data.
This is a narrative review of molecular engineering advances in CAR-T cell design for hematological malignancies, solid tumors, chronic viral infections, and autoimmune diseases. It synthesizes conceptual strategies—including receptor engineering, genome editing, metabolic reprogramming, and synthetic circuits—intended to overcome known barriers to efficacy, but presents no new clinical trial data, outcome metrics, or comparative evidence to support specific recommendations.
Narrative review article. Patients with hematological malignancies, solid tumors, chronic viral infections, and autoimmune diseases (described as target populations for future application, not studied in this review).
CAR-T therapy has transformed hematological malignancy treatment but broader application constrained by antigen heterogeneity, immunosuppressive microenvironments, T-cell exhaustion, limited persistence, and toxicities Engineering strategies increasingly integrated to generate context-specific cellular therapies for cancer, autoimmune diseases, and chronic viral infections Next-generation approaches will integrate antigen recognition, cellular fitness, immune regulation, and longevity beyond maximizing cytotoxic activity alone
CAR-T therapy has transformed hematological malignancy treatment but broader application constrained by antigen heterogeneity, immunosuppressive microenvironments, T-cell exhaustion, limited persistence, and toxicities
This review offers a conceptual framework and research directions for CAR-T engineering but should not be interpreted as reporting clinical efficacy or changing current treatment protocols. Clinicians should use this to understand the landscape of emerging engineering approaches and their theoretical rationale, pending rigorous clinical validation.
A narrative review synthesizing advances in CAR-T engineering strategies for multiple disease contexts, offering conceptual direction rather than new empirical evidence or clinical outcomes.
As stated by the source record.
This review offers a conceptual framework and research directions for CAR-T engineering but should not be interpreted as reporting clinical efficacy or changing current treatment protocols. Clinicians should use this to understand the landscape of emerging engineering approaches and their theoretical rationale, pending rigorous clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, yet its broader application to solid tumors, chronic viral infections, and autoimmune diseases remains constrained by antigen heterogeneity, immunosuppressive tissue microenvironments, T-cell exhaustion, limited persistence, and treatment-associated toxicities. These challenges have shifted the field from optimizing individual receptor constructs toward engineering CAR-T cells as programmable immune systems capable of adapting to diverse disease contexts. This review synthesizes recent advances in molecular engineering strategies that enhance CAR-T cell function beyond conventional receptor design. We discuss how receptor engineering, genome editing, transcriptional and epigenetic regulation, metabolic reprogramming, synthetic gene circuits, and safety-control platforms collectively reshape CAR-T cell fate, persistence, and therapeutic efficacy. Rather than functioning independently, these engineering strategies are increasingly integrated to generate context-specific cellular therapies capable of adapting to diverse disease environments, including cancer, autoimmune diseases, and chronic viral infections. We also highlight the potential for translation into clinical practice or clinical translation and discuss the major challenges associated with clinical implementation. Next-generation CAR-T therapies will increasingly integrate molecular engineering strategies or will rely on molecular engineering strategies to integrate antigen recognition, cellular fitness, immune regulation, and longevity rather than simply maximizing cytotoxic activity. Recent advances in programmable cellular engineering coupled with rigorous clinical evaluation as well as scalable manufacturing technologies or scalable manufacturing platforms in the treatment of other diseases beyond oncology will facilitate the development of safer, more durable, and broadly applicable cellular therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.